Genetic Safety Study of Chlorpromazine.
- Author:
Han Gyu KIM
1
;
Yun Hee SHON
;
Kwang Heun LEE
;
Tae Ho YOON
;
Kyung Soo NAM
Author Information
1. National Bukog Mental Hospital, Bukog, Korea.
- Publication Type:Original Article
- Keywords:
Chlorpromazine;
Ames test;
Recassay;
SOS umu test;
Host-mediated assay
- MeSH:
beta-Galactosidase;
Biotransformation;
Chlorpromazine*;
DNA;
DNA Damage;
Operon;
Plasmids
- From:Journal of Korean Neuropsychiatric Association
2000;39(3):629-637
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECT: The aim of this study is to determine whether exposure to chlorpromazine causes mutagenicity and genetic disorders. METHOD: Ames (Salmonella typhimurium) test and Rec assay (Bacillus subtilis) were used as indicators for DNA damage. Furthermore, the levels of umu operon expression by measuring the beta-galactosidase activity were monitered with the SOS umu test using S. typhimurium 1535 containing plasmid pSK1002. And the host-mediated assay was used to investigate the muta-genicity of chlorpromazine after the activation with in vivo metabolic systems. RESULTS: From the results, chlorpromazine did not affect DNA of S. typhimurium and B. subtilis strains and showed no mutagenicity at the all concentrations tested. These phenomena was also similar to that after metabolic activation of chlorpromazine in in vivo system. CONCLUSION: These results suggested that chlorpromazine did not show the mutagenicity and genotoxicity by four different methods used in this study.
